Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer

Journal of Ovarian Research

Volumn 3, Issue 1, 2010, Pages

  Gupta, Digant ^a   Lammersfeld, Carolyn A ^a   Vashi, Pankaj G ^a   Braun, Donald P ^a  

^a CANCER TREATMENT CENTERS OF AMERICA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ASSESSMENT; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MONITORING; MULTIMODALITY CANCER THERAPY; NUTRITIONAL SUPPORT; OVARY CANCER; OVERALL SURVIVAL; PHYSIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSOCIAL CARE; SPIRITUAL CARE;

EID: 77957737011     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-3-22     Document Type: Article

References (37)

1. Cancer statistics, 2008. A Jemal R Siegel E Ward Y Hao J Xu T Murray MJ Thun, CA Cancer J Clin 2008 58 71 96 10.3322/CA.2007.0010 18287387
2. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. BK Edwards ML Brown PA Wingo HL Howe E Ward LA Ries D Schrag PM Jamison A Jemal XC Wu C Friedman L Harlan J Warren RN Anderson LW Pickle, J Natl Cancer Inst 2005 97 1407 1427 10.1093/jnci/dji289 16204691
3. Rates and risks of ovarian cancer in subgroups of white women in the United States. The Collaborative Ovarian Cancer Group. P Hartge AS Whittemore J Itnyre L McGowan D Cramer, Obstet Gynecol 1994 84 760 764 7936508
4. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. A van Dalen J Favier A Burges U Hasholzner HW de Bruijn D Dobler-Girdziunaite VH Dombi D Fink M Giai P McGing A Harlozinska C Kainz J Markowska R Molina C Sturgeon A Bowman R Einarsson, Gynecol Oncol 2000 79 444 450 10.1006/gyno.2000.5982 11104617
5. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. SM Eisenkop NM Spirtos RL Friedman WC Lin AL Pisani S Perticucci, Gynecol Oncol 2003 90 390 396 10.1016/S0090-8258(03)00278-6 12893206
6. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. RF Ozols BN Bundy BE Greer JM Fowler D Clarke-Pearson RA Burger RS Mannel K DeGeest EM Hartenbach R Baergen, J Clin Oncol 2003 21 3194 3200 10.1200/JCO.2003.02.153 12860964
7. The National Cancer Data Base report on ovarian cancer. American College of Surgeons Commission on Cancer and the American Cancer Society. HE Averette MF Janicek HR Menck, Cancer 1995 76 1096 1103 10.1002/1097-0142(19950915)76: 6<1096::AID-CNCR2820760626>3.0.CO;2-4 8625213
8. Carcinoma of the ovary. AP Heintz F Odicino P Maisonneuve U Beller JL Benedet WT Creasman HY Ngan S Pecorelli, Int J Gynaecol Obstet 2003 83 Suppl 1 135 66 10.1016/S0020-7292(03)90118-4 14763172
9. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. CL Kosary, Semin Surg Oncol 1994 10 31 46 10.1002/ssu.2980100107 8115784
10. The scientific basis of early detection of epithelial ovarian cancer: the National Ovarian Cancer Early Detection Program (NOCEDP). DA Fishman K Bozorgi, Cancer Treat Res 2002 107 3 28 11775458
11. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. KH Lu AP Patterson L Wang RT Marquez EN Atkinson KA Baggerly LR Ramoth DG Rosen J Liu I Hellstrom D Smith L Hartmann D Fishman A Berchuck R Schmandt R Whitaker DM Gershenson GB Mills RC Bast Jr, Clin Cancer Res 2004 10 3291 3300 10.1158/1078-0432.CCR-03- 0409 15161682
12. Abstracts of the first scientific workshop of the Early Detection Research Network. Dis Markers 2001 17 3 38 September 2000 11381202
13. Tumor markers in the management of patients with ovarian cancer. MK Tuxen G Soletormos P Dombernowsky, Cancer Treat Rev 1995 21 215 245 10.1016/0305-7372(95)90002-0 7656266
14. New tumor markers: CA125 and beyond. RC Bast Jr D Badgwell Z Lu R Marquez D Rosen J Liu KA Baggerly EN Atkinson S Skates Z Zhang A Lokshin U Menon I Jacobs K Lu, Int J Gynecol Cancer 2005 15 Suppl 3 274 81 10.1111/j.1525-1438. 2005.00441.x 16343244
15. Cancer antigen 125 and prognosis. E Hogdall, Curr Opin Obstet Gynecol 2008 20 4 8 10.1097/GCO.0b013e3282f2b124 18196998
16. Prechemotherapy serum CA125 level as a predictor of survival outcome in epithelial carcinoma of the ovary. NG Davidson S Khanna PH Kirwan D Bircumshaw, Clin Oncol (R Coll Radiol) 1991 3 32 36 2001340
17. Cancer-associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma. B Gronlund H Dehn CK Hogdall SA Engelholm M Jorgensen B Norgaard-Pedersen EV Hogdall, Int J Gynecol Cancer 2005 15 836 843 10.1111/j.1525-1438.2005.00145.x 16174233
18. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. AP Makar GB Kristensen J Kaern OP Bormer VM Abeler CG Trope, Obstet Gynecol 1992 79 1002 1010 1579296
19. The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma. F Badulescu A Badulescu M Schenker CF Popescu Z Stoica, Rom J Morphol Embryol 2005 46 329 334 16688372
20. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. MM Juretzka RR Barakat DS Chi A Iasonos J Dupont NR Abu-Rustum EA Poynor C Aghajanian D Spriggs ML Hensley P Sabbatini, Gynecol Oncol 2007 104 176 180 10.1016/j.ygyno.2006.07. 027 16996584
21. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer. HS Kim NH Park HH Chung JW Kim YS Song SB Kang, Onkologie 2008 31 315 320 10.1159/000131270 18547972
22. Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer. S Colakovic V Lukic L Mitrovic S Jelic S Susnjar J Marinkovic, Int J Biol Markers 2000 15 147 152 10883888
23. Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors. JM Ferrero R Largillier A Ramaioli P Heudier E Teissier M Namer, Bull Cancer 1997 84 722 728 9339198
24. Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study. JM Riedinger N Eche JP Basuyau I Dalifard K Hacene MF Pichon, Gynecol Oncol 2008 109 194 198 10.1016/j.ygyno.2008.01.035 18329083
25. A risk model for ovarian carcinoma patients using CA 125: time to normalization renders second-look laparotomy redundant. G Frasci S Conforti F Zullo P Mastrantonio G Comella P Comella G Persico RV Iaffaioli, Cancer 1996 77 1122 1130 10.1002/(SICI)1097-0142(19960315)77:6<1122::AID-CNCR18>3.0.CO;2- 3 8635133
26. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. JM Riedinger J Wafflart G Ricolleau N Eche H Larbre JP Basuyau I Dalifard K Hacene MF Pichon, Ann Oncol 2006 17 1234 1238 10.1093/annonc/mdl120 16766592
27. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. A Gadducci P Zola F Landoni T Maggino E Sartori T Bergamino R Cristofani, Gynecol Oncol 1995 58 42 47 10.1006/gyno.1995.1181 7789889
28. CA-125 AUC as a new prognostic factor for patients with ovarian cancer. A Mano A Falcao I Godinho J Santos F Leitao C Oliveira M Caramona, Gynecol Oncol 2005 97 529 534 10.1016/j.ygyno.2005.01.040 15863156
29. CA-125 AUC as a predictor for epithelial ovarian cancer relapse. A Mano A Falcao I Godinho J Santos F Leitao C de Oliveira M Caramona, Cancer Biomark 2008 4 73 81 18503158
30. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. BC Cooper AK Sood CS Davis JM Ritchie JI Sorosky B Anderson RE Buller, Obstet Gynecol 2002 100 59 64 10.1016/S0029-7844(02)02057-4 12100804
31. Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre. N Osman N O'Leary E Mulcahy N Barrett F Wallis K Hickey R Gupta, Ir Med J 2008 101 245 247 18990955
32. Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer. AL Petri E Hogdall IJ Christensen SK Kjaer J Blaakaer CK Hogdall, APMIS 2006 114 359 363 10.1111/j.1600-0463.2006.apm-397.x 16725012
33. Serum CA 125 levels and survival in advanced ovarian cancer. K Munstedt M Krisch S Sachsse H Vahrson, Arch Gynecol Obstet 1997 259 117 123 10.1007/BF02505319 9187463
34. CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. P Sevelda M Schemper J Spona, Am J Obstet Gynecol 1989 161 1213 1216 2589442
35. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. M Markman M Federico PY Liu E Hannigan D Alberts, Gynecol Oncol 2006 103 195 198 10.1016/j.ygyno.2006.02.024 16595148
36. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. JM Riedinger F Bonnetain JP Basuyau N Eche H Larbre I Dalifard J Wafflart G Ricolleau MF Pichon, Ann Oncol 2007 18 881 885 10.1093/annonc/mdl500 17301071
37. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). GJ Rustin ME van der Burg, J Clin Oncol 2009 27 18s, suppl; abstr 1